Antibody-based therapy for type-2 diabetes

• Research unit: INNOSUISSE
• Project number: 13750.1;12 PFFLE-LS

Short description (German)

Antibody-based therapy for type-2 diabetes

Short description (English)

Antibody-based therapy for type-2 diabetes

Abstract (German)

The project focuses on the development of an immunotherapy targeting toxic aggregates of islet amyloid polypeptide which are associated with the loss of pancreatic beta-cells in type-2 diabetes patients. Combining Neurimmune¿s expertise in the discovery and validation of human antibodies and academic partners' know-how in diabetes and amyloidosis research, the joint program is aimed at providing in vivo proof-ofconcept for this novel therapeutic strategy for type-2 diabetes.

Abstract (English)

The project focuses on the development of an immunotherapy targeting toxic aggregates of islet amyloid polypeptide which are associated with the loss of pancreatic beta-cells in type-2 diabetes patients. Combining Neurimmune¿s expertise in the discovery and validation of human antibodies and academic partners' know-how in diabetes and amyloidosis research, the joint program is aimed at providing in vivo proof-ofconcept for this novel therapeutic strategy for type-2 diabetes.